Live attenuated hepatitis A vaccines developed in China

References

• Fiore AE, Wasley A, Bell BP, Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:RR-7 1 - 23; PMID: 16708058
   PubMedGoogle Scholar
• Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 2004; 132:1005 - 22; http://dx.doi.org/10.1017/S0950268804002857; PMID: 15635957
   PubMed Web of Science ®Google Scholar
• Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol 2005; 34:600 - 9; http://dx.doi.org/10.1093/ije/dyi062; PMID: 15831565
   PubMed Web of Science ®Google Scholar
• Kunasol P, Cooksley G, Chan VF, Isahak I, John J, Loleka S, Villar EP, Poovorawan Y, Seong NH, Sulaiman HA, et al. Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Southeast Asian J Trop Med Public Health 1998; 29:255 - 62; PMID: 9886108
   PubMedGoogle Scholar
• Rein DB, Fiore AE, Bell BP. What’s next for the hepatitis A vaccine?. Lancet 2006; 367:546 - 8; http://dx.doi.org/10.1016/S0140-6736(06)68196-8; PMID: 16488780
   PubMed Web of Science ®Google Scholar
• Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 1992; 10:Suppl 1 S99 - 101; http://dx.doi.org/10.1016/0264-410X(92)90557-Z; PMID: 1335671
   PubMedGoogle Scholar
• Armstrong ME, Giesa PA, Davide JP, Redner F, Waterbury JA, Rhoad AE, Keys RD, Provost PJ, Lewis JA. Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. J Hepatol 1993; 18:Suppl 2 S20 - 6; http://dx.doi.org/10.1016/S0168-8278(05)80373-3; PMID: 8182268
   PubMedGoogle Scholar
• Vidor E, Fritzell B, Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection 1996; 24:447 - 58; http://dx.doi.org/10.1007/BF01713047; PMID: 9007593
   PubMed Web of Science ®Google Scholar
• Glück R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr.. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 1992; 90:2491 - 5; http://dx.doi.org/10.1172/JCI116141; PMID: 1334977
   PubMed Web of Science ®Google Scholar
• Mao JS, Dong DX, Zhang HY, Chen NL, Zhang XY, Huang HY, Xie RY, Zhou TJ, Wan ZJ, Wang YZ, et al. Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 1989; 159:621 - 4; http://dx.doi.org/10.1093/infdis/159.4.621; PMID: 2538518
   PubMed Web of Science ®Google Scholar
• Hu MD, Zhang X, Sun BF, He JF, Yin PP, Lu XX, Wu WH, Wang PF, Zhao KJ, Wang W, et al. Observation of live attenuated hepatitis A vaccine in human. Zhong Hua Yu Fang Yi Xue Za Zhi 1993; 27:65 - 8
   PubMedGoogle Scholar
• Qian W, Chen J, Cai MJ. Safety and immunogenicity of live, attenuated hepatitis A (H2 strain) vaccine in Rhysus monkeys and humans. Shang Hai Shi Yan Dong Wu Ke Xue 1998; 18:227
   Google Scholar
• Dong DX, Cao YY, Lian YH, Zhou DJ, Huang XQ, Tan SG, Chen TQ, Luo QS, Bai HZ, Yang JS, et al. Residual virulence and its reversion study of live attenuated hepatitis A vaccine (H2 strian). Chin Med Sci J 1999; 14:11 - 6
   Google Scholar
• Hu MD, Sun BF, Qiu ZF. Study on the live attenuated hepatitis A vaccine candidate: attenuation and monky test. Shang Hai Yi Xue 1988; 11.
   Google Scholar
• Provost PJ, Bishop RP, Gerety RJ, Hilleman MR, McAleer WJ, Scolnick EM, Stevens CE. New findings in live, attenuated hepatitis A vaccine development. J Med Virol 1986; 20:165 - 75; http://dx.doi.org/10.1002/jmv.1890200208; PMID: 3021899
   PubMed Web of Science ®Google Scholar
• Karron RA, Daemer R, Ticehurst J, D’Hondt E, Popper H, Mihalik K, Phillips J, Feinstone S, Purcell RH. Studies of prototype live hepatitis A virus vaccines in primate models. J Infect Dis 1988; 157:338 - 45; http://dx.doi.org/10.1093/infdis/157.2.338; PMID: 2826614
   PubMed Web of Science ®Google Scholar
• Sjogren MH, Purcell RH, McKee K, Binn L, Macarthy P, Ticehurst J, Feinstone S, Caudill J, See A, Hoke C, et al. Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate. Vaccine 1992; 10:Suppl 1 S135 - 7; http://dx.doi.org/10.1016/0264-410X(92)90568-5; PMID: 1335645
   PubMedGoogle Scholar
• Tang CH, Mao JS, Chai SA, Chen Y, Zhuang FC. Molecular evolution of hepatitis A virus in a human diploid cell line. World J Gastroenterol 2007; 13:4630 - 5; PMID: 17729420
   PubMed Web of Science ®Google Scholar
• Huang XQ, Lian YH, Wang QL, Wang X, Yang JS, Bai HZ. YY C. Experimental in vivo passage of H2 strain of live attenuated vaccine of hepatitis A in common marmosets. Zhong Hua Yu Fang Yi Xue Za Zhi 1997; 31:260 - 2
   PubMedGoogle Scholar
• Provost PJ, Banker FS, Wadsworth CW, Krah DL. Further evaluation of a live hepatitis A vaccine in marmosets. J Med Virol 1991; 34:227 - 31; http://dx.doi.org/10.1002/jmv.1890340406; PMID: 1658214
   PubMed Web of Science ®Google Scholar
• Qian W, Chen J, Liu CJ, Lin CX, Cai MJ. Observation on 22 batches of live, attenuated hepatitis A vaccine (H2 strain) in human. Zhe Jiang Shen Yi Xue Ke Xue Yuan Xue Bao 1998; 9:13 - 4
   Google Scholar
• Chen YZ, Cui YJ, Tang Q, Zhou ZQ, Liu LJ, Wu JF, Liu XL, Dong M, Liu ZH, Liu JY. Adverse Reaction and Immunogenicity Induced by Freeze-dried Live Attenuated Hepatitis A Vaccine. Zhong Guo Sheng Wu Zhi Pin Xue Za Zhi 2009; 22:914 - 6
   Google Scholar
• Cai SA, Zhang HC, Zhang SY, Chen NL, Huang HY, Liu CJ, Xie RY, Mao JS. Several genetic characteristics of live, attenuated hepatitis A vaccine, H2 strain. Zhonghua Yi Xue Za Zhi (Taipei) 1993; 73:335 - 7
   Google Scholar
• Mao JS, Chai SA, Xie RY, Chen NL, Jiang Q, Zhu XZ, Zhang SY, Huang HY, Mao HW, Bao XN, et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine 1997; 15:944 - 7; http://dx.doi.org/10.1016/S0264-410X(96)00304-0; PMID: 9261939
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu ZY, Ouyang PY, Zhao SJ, Wu WZ. [Studies on re-immunization with live attenuated hepatitis A vaccine]. Zhonghua Yu Fang Yi Xue Za Zhi 1998; 32:162 - 4; PMID: 10322791
   PubMedGoogle Scholar
• Wang XY, Meng ZD, Li RC, Ma JC, Luo D, Liu HB, Gong J, Xu ZY, Zhang YL, Han CQ, et al. Comparison of immunogenicity between live attenuated hepatitis A vaccine and inactivated hepatitis A vaccine. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 80:422 - 4
   Google Scholar
• Wang XY, Ma JC, Zhang Y, Zhang YL, Zhang YW, Han CQ, Xing ZC, Chen JC, Zhao SJ, Xu ZY. [Immunogenicity and long-term persistence of anti-HAV in groups with different attenuated and inactived hepatitis A vaccine dosage]. Zhonghua Liu Xing Bing Xue Za Zhi 2001; 22:111 - 3; PMID: 11860857
   PubMedGoogle Scholar
• Murphy P, Nowak T, Lemon SM, Hilfenhaus J. Inactivation of hepatitis A virus by heat treatment in aqueous solution. J Med Virol 1993; 41:61 - 4; http://dx.doi.org/10.1002/jmv.1890410113; PMID: 8228940
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin XM, Zhao SJ, Ouyang PY, Xu ZY. Imunogenicity of a live attenuated hepatitis A vaccine in humans. He Bei Yi Ke Da Xue Xue Bao 1997; 18:209 - 10
   Google Scholar
• Wang XY, Xu ZY, Ma JC, von Seidlein L, Zhang Y, Hao ZY, Han OP, Zhang YL, Tian MY, Ouyang PY, et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 2007; 25:446 - 9; http://dx.doi.org/10.1016/j.vaccine.2006.08.004; PMID: 16949710
   PubMed Web of Science ®Google Scholar
• Jiang WP, Chen JT, Wang X, Wang YL, Liu Y, Chen WY, Xu WG, Qiu YZ, Yin WD. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. Vaccine 2008; 26:2297 - 301; http://dx.doi.org/10.1016/j.vaccine.2007.11.008; PMID: 18395305
   PubMed Web of Science ®Google Scholar
• Xin YJ, He YH, Zhuang FC, Gao LM, Qian W, Tang CH, Chen YQ, Chai SA, Mao JS. Cellular immune responses in humans immunized with the lyophlized, live, attenuated hepatitis A vaccine (H2 strain). Zhong Guo Yi Miao He Mian Yi 2008; 14:246 - 9
   Google Scholar
• Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, Shouval D, Ellerbeck E, Block SL, Bishop R, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 1993; 18:Suppl 2 S51 - 5; http://dx.doi.org/10.1016/S0168-8278(05)80379-4; PMID: 8182275
   PubMedGoogle Scholar
• Wu WZ, Xu ZY, Xia JP, Ouyang PY, Min XJ, Lin XM, Liu Y. Field evaluation on the efficacy of live attenuated hepatitis A vaccine. Zhong Guo Gong Gong Wei Sheng 1996; 12:535 - 6
   Google Scholar
• Xu ZY, Wang XY, Li RC, Meng ZD, Zhang Y, Gong J, Ma JC, Li YT, Zhao SJ, Li YP, et al. Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H2 Strains and LA-1 strains). Zhonghua Yi Xue Za Zhi (Taipei) 2002; 82:678 - 81
   Google Scholar
• Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapong T, Safary A, Tang DB, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1328 - 34; http://dx.doi.org/10.1001/jama.1994.03510410040030; PMID: 8158817
   PubMed Web of Science ®Google Scholar
• Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453 - 7; http://dx.doi.org/10.1056/NEJM199208133270702; PMID: 1320740
   PubMed Web of Science ®Google Scholar
• Meng ZD, Yao JF, Zhao YL, Guo JJ, Wang XY, Cai SA, Liu HB, Duo CG, Xu YG, Mu WD, et al. Further study on efficacy of attenuated live hepatitis A vaccine. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 80:9 - 11
   Google Scholar
• Xu ZY, Wang XY, Zhao SJ. Protective efficacy of and strategy for immunization with live, attenuated hepatitis A vaccines. Zhonghua Liu Xing Bing Xue Za Zhi 2002; 23:394 - 6
   Google Scholar
• Xu ZY, Wang JX, Jiang SP, Fang YM, Yu YF. Detection of HAV in stool of a subclinical infected child. Chung Hua Chuan Jan Ping Tsa Chih 1984; 2:45 - 6
   Google Scholar
• Zhuang FC, Mao ZA, Jiang LM, Wu J, Chen YQ, Jiang Q, Chen NL, Chai SA, Mao JS. [Long-term immunogenicity and effectiveness of live attenuated hepatitis A vaccine (H2-strain)-a study on the result of 15 years’ follow up]. Zhonghua Liu Xing Bing Xue Za Zhi 2010; 31:1332 - 5; PMID: 21223658
   PubMedGoogle Scholar
• Xu ZY, Wang XY, Liu CQ, Li YT, Zhuang FC. Decline in the risk of hepatitis A virus infection in China, a country with booming economy and changing lifestyles. J Viral Hepat 2008; 15:Suppl 2 33 - 7; http://dx.doi.org/10.1111/j.1365-2893.2008.01026.x; PMID: 18837831
   PubMedGoogle Scholar
• Wang XY, Ma JC, Xu ZY, Liu HB, Zhang YL, Han CQ, Zhang YW, Xing ZC, Chen JC, Meng ZD, et al. Effectiveness of Post-exposure Prophylaxis Using Live Attenuated Hepatitis A Vaccine(H2 Strain) among Schoolchildren. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 82:955 - 7
   Google Scholar
• Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, Shouval D, Bonanni P, Connor B, Cooksley G, et al, International Consensus Group on Hepatitis A Virus Immunity. Hepatitis A booster vaccination: is there a need?. Lancet 2003; 362:1065 - 71; http://dx.doi.org/10.1016/S0140-6736(03)14418-2; PMID: 14522539
   PubMed Web of Science ®Google Scholar
• Mor Z, Srur S, Dagan R, Rishpon S. Hepatitis A disease following the implementation of universal vaccination: who is at risk?. J Viral Hepat 2010; 17:293 - 7; http://dx.doi.org/10.1111/j.1365-2893.2009.01176.x; PMID: 19691457
   PubMed Web of Science ®Google Scholar
• Zhuang FC, Jiang Q, Gong YP, Mo SH, Xi YJ, Qian W, Chen NL, Zhang SY, Cai SA, Mao JS. [Epidemiological effects of live attenuated hepatitis A vaccine (H(2)-strain): results of A 10-year observation]. Zhonghua Liu Xing Bing Xue Za Zhi 2001; 22:188 - 90; PMID: 11860874
   PubMedGoogle Scholar